All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
On the 2nd of October 2019, the European Patent Office has issued a Notice of Allowance for EU Patent for the use of cannabidiol (CBD, a non-psychoactive component of cannabis with immunosuppressive properties) for the prevention and treatment of acute graft-versus-host disease (aGvHD).1 There are currently no approved therapies for the prevention and very few licensed drugs for the treatment of aGvHD. Therefore, the development of efficient therapies to prevent and treat aGvHD is a major goal of allogeneic bone marrow transplantation.2
The company has stated that the new, proprietary CBD product which is an oral formulation in olive oil, that was designed to overcome previous issues of poor oral bioavailability and stability, has the potential to be used as a treatment option for bone marrow transplant recipients who are at high risk of developing aGvHD.1 CBD has previously been granted orphan drug designation by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and the results for the phase II study (NCT03840512) were previously covered by the GvHD hub.
References